Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CDA | P32320 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5145484 | 0.85 | PYGM (0.49) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL27965304 | 0.85 | PYGM (0.49) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21458099 | 0.82 | PYGM (0.52) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL27760732 | 0.81 | PYGM (0.51) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1932437 | 0.80 | PYGM (0.50) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL1067013 | 0.80 | PYGM (0.52) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21683245 | 0.78 | PYGM (0.48) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL3841360 | 0.78 | PYGM (0.48) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28344680 | 0.78 | PYGM (0.50) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2903546 | 0.78 | PYGM (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2024042489-A1 | CHEMICAL MODIFICATION OF GUIDE RNAS WITH LOCKED NUCLEIC ACID FOR RNA GUIDED NUCLEASE-MEDIATED GENE EDITING | LifeEDIT Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4259105-A1 | IN VIVO TARGETING OF CD4+ -T CELLS FOR MRNA THERAPEUTICS | The Trustees of the University of Pennsylvania (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4228602-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | The Trustees of the University of Pennsylvania (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228601-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | The Trustees of the University of Pennsylvania (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230242899-A1 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | TESSERA THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023015200-A1 | AMNIOTIC FLUID STABILIZED COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY OF THERAPEUTIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022081694-A1 | IN VIVO TARGETING OF FIBROSIS BY ANTI-CD5-TARGETED FAP-CAR T MRNA-LNP | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081699-A1 | IN VIVO TARGETING OF T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081702-A1 | IN VIVO TARGETING OF CD4+-T CELLS FOR MRNA THERAPEUTICS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3891274-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | Arcturus Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118115-A1 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | ARCTURUS THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2013136087-A1 | METHOD AND APPARATUS | BASE4 INNOVATION LTD (GB) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013136088-A1 | METHOD AND APPARATUS | BASE4 INNOVATION LTD (GB) | 2013-09-19 | — | — | WO | disclosed |
| US-20040053872-A1 | Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome | PRIMERT AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1383910-A2 | METHODS FOR THE PREPARATION OF POLYNUCLEOTIDE LIBRAIRIES AND IDENTIFICATION OF LIBRARY MEMBERS HAVING DESIRED CHARACTERISTICS | HERCULES INCORPORATED (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1311672-A1 | NEW SEQUENCES | Primert AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002081643-A2 | METHODS FOR THE PREPARATION OF POLYNUCLEOTIDE LIBRAIRIES AND IDENTIFICATION OF LIBRARY MEMBERS HAVING DESIRED CHARACTERISTICS | HERCULES INCORPORATED (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002016608-A1 | NEW SEQUENCES | PRIMERT AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | PYGM 4500/4885TK2 630/4885SLC28A1 2359/4885 |
| US-20040053872-A1 | Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome | POLRMT, NSUN3, TARBP1 | PYGM 4184/4885TK2 64/4885SLC28A1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.